Here’s Why Gold and Cannabis Stocks Are a Powerful Combo

Stocks like Aphria Inc. (TSX:APHA)(NYSE:APHA) have outperformed their industries. Find out why gold and cannabis makes a strong combined play.

Image source: Getty Images.

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

They’re vastly different on the face of it — two areas of the TSX that traditionally appeal to very different investment types. But today we will be exploring whether 2020 is the year for buying into both gold and cannabis. How well do these two investment themes complement each other? Are there better names to buy and hold than others? And what is it about these industries that makes them recession resistant?

Diversifying across industries strengthens a stock portfolio

Gold and cannabis were two areas that really stood out mid-crash. Cannabis stocks may be down on average by around 23% over the last three months. However, their performance during the crash was surprisingly stubborn, with some names outperforming their sector. Gold saw predictable gains, and many large producers provided islands of stability amid the froth.

The problem with gold and cannabis stocks is that they are both pure plays heavily influenced by spot prices in single commodities. The downside here is that both industries are therefore dangerously overexposed to market forces. However, this can work out if both industries are held together in a portfolio. This is because they exist at opposite ends of the risk spectrum.

There is also another reason why gold and cannabis might belong on a single shopping list: resilience during the pandemic. Don’t try and index cannabis, though. The Horizons Marijuana Life Science ETF may have been steadily rising, as risk returned to investors’ shopping lists. However, it’s been down 23% over the past three months. Compare this with Aphria’s market-matching 17% loss over the same period.

Trim the rallies and buy the dips

Investors may be holding out for the bottom. Conversely, some analysts are beginning to wonder whether a recovery is already priced into the market. But there is one strategy that can walk a middle line between caution and bullishness. It’s a simple method that involves building on weakness and trimming underperformers on strength.

By buying the dips and selling the rallies, investors can gradually optimize a portfolio for any market. Investors should add big names in both sectors to a post-rally watch list. Front-runners include high-growth names Kirkland Lake Gold and world-class producers like Newmont. These stocks also satisfy a passive-income strategy. Kirkland’s yield of 1.24% is tempting, while Newmont pays a 1.5% dividend.

Earnings season provides opportunities to ride upside. However, investors may want to wait for the momentum — both positive and negative — to dissipate before building or trimming positions. Long-term portfolios geared towards years of steady growth should be built on a bedrock of value. One benefit of the market crash is that it highlighted just how much certain sectors were really worth.

Appetite for risk is likely to fluctuate, with gold and cannabis likely to part company in opposite directions. But this is what makes them a complementary tag team. As gold prices rise on recession fears, cannabis is likely to depreciate in value. And when the market rallies on vaccine hopes, the reverse will hold. Investors can use both scenarios to build and trim, gradually optimizing their positions.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Victoria Hetherington has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »